PRF TECHNOLOGIES LTD

PRFXNASDAQ

🏆 #4058 by market capUS Equity

$1.10▲ $0.05 (+4.76%)

🌙 After hours$1.07▼ 2.73%Regular close · extended-hours price shown

1h—

24h▲ 4.8%

7d—

14d—

30d—

1y—

🏦Market Cap

$3M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

No chart data available for PRFX.

Trading Snapshot

Day Range: $1.10 – $1.12
52-Week Range: $0.97 – $17.95
Volume: $4.26B
Avg Volume: $5.04B
Shares Outstanding: 3.0M
Next Earnings: Oct 1, 2026

Fundamentals Snapshot

Annual Revenue: $17,000
Last Q Revenue: $17,000
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-12.92
Dividend Yield: —

Why Investors Own PRFX

✓High-growth profile — revenue up +53.9% YoY with expanding US Equity exposure.
✓Healthy economics — 52% gross margin and 8% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$17,000▲ +57.7% YoY

Gross Margin (TTM)

51.8%▲ +3.6% YoY

Operating Income (TTM)

$5,882▲ +57.7% YoY

Free Cash Flow (TTM)

$1,428▲ +57.7% YoY

About PRF TECHNOLOGIES LTD

PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.

🦦